Seeking Alpha

Celsion (CLSN) -78.1% premarket on news that ThermoDox in combination with radiofrequency...

Celsion (CLSN) -78.1% premarket on news that ThermoDox in combination with radiofrequency ablation did not meet the primary endpoint of the Phase III HEAT Study in patients with primary liver cancer. The study was designed to show a 33% improvement in progression-free survival. CLSN is conducting additional analyses of data from the trial to assess the future strategic value of ThermoDox.
Comments (5)
  • This was no surprise. Some of the more serious commentators have been expecting as much for a number of weeks now.
    31 Jan 2013, 09:25 AM Reply Like
  • I will ALWAYS own a solid dividend paying stock before I own any of these gambling stocks.
    99% of the time gamblers always lose.

     

    Not worth it.
    31 Jan 2013, 09:30 AM Reply Like
  • CLSN is conducting additional analyses of data from the trial to assess the future strategic value of ThermoDox.
    **********************...
    And how long will this take, months? Years? Any specifics released? Or is this just camouflage for the company stalling before they close the doors?
    31 Jan 2013, 09:58 AM Reply Like
  • No surprise. The drug they used, doxorubicin, has never been shown to be effective against the disease they targeted. Makes you wonder what they were thinking.
    31 Jan 2013, 11:13 AM Reply Like
  • Time to move on. CLSN is a dead horse. CTIX has a bright future
    31 Jan 2013, 11:14 AM Reply Like
DJIA (DIA) S&P 500 (SPY)